The role of furin in papillomavirus infection

Future Microbiology

Volumn 4, Issue 10, 2009, Pages 1255-1262

  Day, Patricia M ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Basement membrane; Extracellular matrix; Furin; Heparan sulfate proteoglycan; Papillomavirus; Proprotein convertase

Indexed keywords

FURIN; SERINE PROTEINASE;

CANCER RISK; CELL SURFACE; CELL TRANSPORT; DISEASE ASSOCIATION; KERATINOCYTE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN FUNCTION; REVIEW; UTERINE CERVIX CANCER; VIRION; VIRUS ENTRY; VIRUS INFECTION; WART VIRUS;

CAPSID PROTEINS; FEMALE; FURIN; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRUS INTERNALIZATION;

HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; PAPILLOMAVIRIDAE;

EID: 74749099125     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.86     Document Type: Review

References (49)

1. De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H: Classification of papillomaviruses. Virology 324(1), 17-27 (2004).
2. Zur Hausen H: Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111(6), 581-587 (1999).
3. Buck CB, Cheng N, Thompson CD et al.: Arrangement of L2 within the papillomavirus capsid. J. Virol. 82(11), 5190-5197 (2008).
4. Kirnbauer R, Taub J, Greenstone H et al.: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67(12), 6929-6936 (1993).
5. Day PM, Lowy DR, Schiller JT: Papillomaviruses infect cells via a clathrindependent pathway. Virology 307(1), 1-11 (2003).
6. Joyce JG, Tung JS, Przysiecki CT et al.: The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274(9), 5810-5822 (1999).
7. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M: Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75(3), 1565-1570 (2001).
8. Day PM, Schiller JT: Early events in the papillomaviral lifecycle. In: Papillomavirus Research: From Natural History to Vaccines and Beyond. Campo MS (Ed.). Caister Academic Press, UK 175-192 (2006).
9. Richards RM, Lowy DR, Schiller JT, Day PM: Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl Acad. Sci. USA 103(5), 1522-1527 (2006). ■■ Contains the initial description of the role of furin in papillomavirus infection.
10. Seidah NG, Mayer G, Zaid A et al.: The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40(6-7), 1111-1125 (2008).
11. Seidah NG, Prat A: The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85(7), 685-696 (2007).
12. Nakayama K: Furin: a mammalian subtilisin/kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 327(Pt 3), 625-635 (1997).
13. Zhang X, Fugere M, Day R, Kielian M: Furin processing and proteolytic activation of Semliki Forest virus. J. Virol. 77(5), 2981-2989 (2003).
14. Zybert IA, Van Der Ende-Metselaar H, Wilschut J, Smit JM: Functional importance of dengue virus maturation: infectious properties of immature virions. J. Gen. Virol. 89(Pt 12), 3047-3051 (2008).
15. Buck CB, Thompson CD: Production of papillomavirus-based gene transfer vectors. Curr. Protoc. Cell Biol. Chapter 26, Unit 26 21 (2007). ■ Detailed protocols for papillomavirusbased pseudovirus production are included in this chapter.
16. Buck CB, Thompson CD, Pang Y-YS, Lowy DR, Schiller JT: Maturation of papillomavirus capsids. J. Virol. 79(5), 2839-2846 (2005).
17. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT: Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J. Virol. 82(9), 4638-4646 (2008).
18. Day PM, Lowy DR, Schiller JT: Heparan sulfate-independent cell binding and infection with furin pre-cleaved papillomavirus capsids. J. Virol. 82(24), 12565-12568 (2008).
19. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M: Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77(24), 12961-12967 (2003).
20. Belting M: Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28(3), 145-151 (2003).
21. Payne CK, Jones SA, Chen C, Zhuang X: Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 8(4), 389-401 (2007).
22. Selinka HC, Florin L, Patel HD et al.: Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J. Virol. 81(20), 10970-10980 (2007).
23. Kamper N, Day PM, Nowak T et al.: A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 80(2), 759-768 (2006). ■ Establishes the role of L2 in endosome escape and desmonstrates that a carboxyl region mediates the process.
24. Darshan MS, Lucchi J, Harding E, Moroianu J: The L2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J. Virol. 78(22), 12179-12188 (2004).
25. Roberts JN, Buck CB, Thompson CD et al.: Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13(7), 857-861 (2007). ■■ The murine cervicovaginal model of papillomavirus infection was first described in this manuscript. It was also shown that pseudovirions initially interact with the basement membrane.
26. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM: Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 83(5), 2067-2074 (2009).
27. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM: The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl Acad. Sci. USA (2009) (In Press).
28. Tsuji A, Sakurai K, Kiyokage E et al.: Secretory proprotein convertases PACE4 and PC6a are heparin-binding proteins which are localized in the extracellular matrix. Potential role of PACE4 in the activation of proproteins in the extracellular matrix. Biochim. Biophys. Acta 1645(1), 95-104 (2003).
29. Nour N, Mayer G, Mort JS et al.: The cysteine-rich domain of the secreted proprotein convertases PC5a and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. Mol. Biol. Cell 16(11), 5215-5226 (2005).
30. Mayer G, Hamelin J, Asselin MC et al.: The regulated cell surface zymogen activation of the proprotein convertase PC5a directs the processing of its secretory substrates. J. Biol. Chem. 283(4), 2373-2384 (2008).
31. Creemers JW, Khatib AM: Knockout mouse models of proprotein convertases: unique functions or redundancy? Front. Biosci. 13, 4960-4971 (2008).
32. Bossis I, Roden RB, Gambhira R et al.: Interaction of tsnare syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J. Virol. 79(11), 6723-6731 (2005).
33. Smith JL, Lidke DS, Ozbun MA: Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology 381(1), 16-21 (2008).
34. Campos SK, Ozbun MA: Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One 4(2), e4463 (2009).
35. Spoden G, Freitag K, Husmann M et al.: Clathrin- and caveolin-independent entry of human papillomavirus type 16 - involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3(10), e3313 (2008).
36. Charrin S, Le Naour F, Silvie O, Milhiet PE, Boucheix C, Rubinstein E: Lateral organization of membrane proteins: tetraspanins spin their web. Biochem. J. 420(2), 133-154 (2009).
37. Lorenz HP, Longaker MT: Wounds: biology, pathology, and management. In: Surgery (2nd Edition) Basic Science and Clinical Evidence. Norton JA, Barie PS, Bollinger RR et al. (Eds). Springer, NY, USA 191-208 (2008).
38. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF: Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5(2), e1000318 (2009). ■ Establishes the requirement for completion of mitosis for papillomavirus infection.
39. Vasioukhin V, Bauer C, Yin M, Fuchs E: Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell 100(2), 209-219 (2000).
40. Schelhaas M, Ewers H, Rajamaki Ml, Day PM, Schiller JT, Helenius A: Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog. 4(9), e1000148 (2008).
41. Bernard HU, Calleja-Macias LE, Dunn ST: Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer 118(5), 1071-1076 (2006).
42. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270(2), 254-257 (2000).
43. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS: Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J. Gen. Virol. 77(Pt 7), 1577-1583 (1996).
44. Kawana Y, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Human papillomavirus type 16 minor capsid protein L2 n-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 75(5), 2331-2336 (2001).
45. Pastrana DV, Gambhira R, Buck CB et al.: Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337(2), 365-372 (2005).
46. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T: Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358(2), 266-272 (2007).
47. Jagu S, Karanam B, Gambhira R et al.: Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl Cancer Inst. 101(11), 782-792 (2009). ■ L2 immunogens were compared with virus-like particles and Gardasil® , one of the currently available papillomavirus vaccines, for the ability to protect against infection by multiple human papillomavirus types.
48. Gambhira R, Jagu S, Karanam B et al.: Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 81(21), 11585-11592 (2007).
49. Alphs HH, Gambhira R, Karanam B et al.: Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl Acad. Sci. USA 105(15), 5850-5855 (2008).